CA2978311A1 - Combination of a pd-1 antagonist and eribulin for treating cancer - Google Patents

Combination of a pd-1 antagonist and eribulin for treating cancer Download PDF

Info

Publication number
CA2978311A1
CA2978311A1 CA2978311A CA2978311A CA2978311A1 CA 2978311 A1 CA2978311 A1 CA 2978311A1 CA 2978311 A CA2978311 A CA 2978311A CA 2978311 A CA2978311 A CA 2978311A CA 2978311 A1 CA2978311 A1 CA 2978311A1
Authority
CA
Canada
Prior art keywords
eribulin
breast cancer
pembrolizumab
dose
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2978311A
Other languages
English (en)
French (fr)
Inventor
Junji Matsui
Gursel AKTAN
Vassiliki KARANTZA
RuiRong YUAN
Yasuhiro Funahashi
Erhan BERRAK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Merck Sharp and Dohme LLC
Original Assignee
Eisai R&D Management Co Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55586425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2978311(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Management Co Ltd, Merck Sharp and Dohme LLC filed Critical Eisai R&D Management Co Ltd
Publication of CA2978311A1 publication Critical patent/CA2978311A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA2978311A 2015-03-04 2016-03-03 Combination of a pd-1 antagonist and eribulin for treating cancer Abandoned CA2978311A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562128373P 2015-03-04 2015-03-04
US62/128,373 2015-03-04
US201562264068P 2015-12-07 2015-12-07
US62/264,068 2015-12-07
PCT/US2016/020734 WO2016141209A1 (en) 2015-03-04 2016-03-03 Combination of a pd-1 antagonist and eribulin for treating cancer

Publications (1)

Publication Number Publication Date
CA2978311A1 true CA2978311A1 (en) 2016-09-09

Family

ID=55586425

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2978311A Abandoned CA2978311A1 (en) 2015-03-04 2016-03-03 Combination of a pd-1 antagonist and eribulin for treating cancer

Country Status (13)

Country Link
US (1) US10945990B2 (cg-RX-API-DMAC7.html)
EP (1) EP3265122B1 (cg-RX-API-DMAC7.html)
JP (1) JP6951248B2 (cg-RX-API-DMAC7.html)
KR (1) KR20170122810A (cg-RX-API-DMAC7.html)
CN (1) CN107810013B (cg-RX-API-DMAC7.html)
AU (1) AU2016226157B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017018872A2 (cg-RX-API-DMAC7.html)
CA (1) CA2978311A1 (cg-RX-API-DMAC7.html)
IL (1) IL254133B (cg-RX-API-DMAC7.html)
MX (1) MX386547B (cg-RX-API-DMAC7.html)
RU (1) RU2737216C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201706872SA (cg-RX-API-DMAC7.html)
WO (1) WO2016141209A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5226304B2 (ja) 2004-06-03 2013-07-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 ハリコンドリンｂ類似体の調製用中間体
WO2008156712A1 (en) 2007-06-18 2008-12-24 N. V. Organon Antibodies to human programmed death receptor pd-1
PT2415470T (pt) 2009-03-30 2016-08-31 Eisai R&D Man Co Ltd Composição de lipossomas
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
BR112017018872A2 (pt) 2015-03-04 2018-05-29 Eisai R&D Man Co Ltd combinação de um antagonista pd-1 e eribulina para tratamento de câncer
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
JP6865177B2 (ja) * 2015-06-11 2021-04-28 バイオノミクス リミテッド 医薬組み合わせおよびその使用
WO2017011580A2 (en) 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
EP3449921B1 (en) 2016-04-28 2023-05-31 Eisai R&D Management Co., Ltd. Eribulin for inhibiting tumor growth
US20190263927A1 (en) * 2016-10-14 2019-08-29 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and eribulin for treating urothelial cancer
WO2018075740A1 (en) * 2016-10-21 2018-04-26 Merck Sharp & Dohme Corp. Treating cancer with a combination of pd-1 antagonist and an il-27 antagonist
EP3654967A4 (en) * 2017-07-21 2021-04-21 Eisai R&D Management Co., Ltd. USE OF EIBULIN AND CYCLINE-DEPENDENT KINASE INHIBITORS IN THE TREATMENT OF CANCER
EP3713565A1 (en) 2017-11-20 2020-09-30 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
EP3843718A1 (en) 2018-06-15 2021-07-07 The Board Of Regents Of The University Of Texas System Methods of treating and preventing melanoma with s-equol
WO2019240871A1 (en) * 2018-06-15 2019-12-19 The Board Of Regents Of The University Of Texas System Methods of treating and preventing breast cancer with s-equol
US11083705B2 (en) * 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
CN114650815A (zh) * 2019-10-28 2022-06-21 Enzychem生命科学株式会社 癌症治疗的方法及组成物
WO2025049528A1 (en) * 2023-08-29 2025-03-06 Cullinan Amber Corp. Combination therapies for cancer

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
AU762998B2 (en) 1998-06-17 2003-07-10 Eisai R&D Management Co., Ltd. Macrocyclic analogs and methods of their use and preparation
US8097648B2 (en) * 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
AU764211C (en) 1998-12-01 2006-03-30 Abbvie Biotherapeutics Inc. Humanized antibodies to gamma-interferon
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
KR20050107399A (ko) 2003-01-23 2005-11-11 오노 야꾸힝 고교 가부시키가이샤 인간 ｐｄ-1에 대하여 특이성을 갖는 물질
JP5226304B2 (ja) 2004-06-03 2013-07-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 ハリコンドリンｂ類似体の調製用中間体
EP1896582A4 (en) * 2005-05-09 2009-04-08 Ono Pharmaceutical Co HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
WO2008156712A1 (en) 2007-06-18 2008-12-24 N. V. Organon Antibodies to human programmed death receptor pd-1
SG10201811715YA (en) 2007-10-03 2019-02-27 Eisai R&D Man Co Ltd Intermediates and methods for the synthesis of halichondrin b analogs
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
EP2328919A2 (en) 2008-08-25 2011-06-08 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
TW202442680A (zh) 2008-12-09 2024-11-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
BR112012018232B8 (pt) 2010-01-26 2023-01-10 Eisai R&D Man Co Ltd Compostos derivados de furo [3,2-b] pirano úteis na síntese de análogos de halicondrina b e métodos de sintetização de er-80402 e de eribulina
EP2680839A1 (en) 2011-03-02 2014-01-08 Morphotek, Inc. Co -administration of eribulin and farletuzumab for the treatment of breast cancer
EP2686441B1 (en) * 2011-03-18 2019-05-08 Eisai R&D Management Co., Ltd. Methods and uses for predicting response to eribulin
DK2691112T3 (en) 2011-03-31 2018-07-30 Merck Sharp & Dohme STABLE FORMULATIONS OF ANTIBODIES AGAINST HUMAN PD (PROGRAMMED DEATH) 1- RECEPTOR AND RELATED TREATMENTS
TWI835048B (zh) 2011-08-01 2024-03-11 美商建南德克公司 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
KR20150090921A (ko) * 2012-12-04 2015-08-06 에자이 알앤드디 매니지먼트 가부시키가이샤 유방암 치료에서 에리불린의 용도
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
RS56531B1 (sr) * 2013-03-14 2018-02-28 Bristol Myers Squibb Co Kombinacija dr5 agoniste i anti-pd-1 antagoniste i načini primene
WO2014193898A1 (en) 2013-05-31 2014-12-04 Merck Sharp & Dohme Corp. Combination therapies for cancer
US20160120871A1 (en) 2013-06-11 2016-05-05 Novartis Ag Pharmaceutical combinations of a pi3k inhibitor and a microtubule destabilizing agent
WO2014208774A1 (en) 2013-06-26 2014-12-31 Eisai R&D Management Co., Ltd. Use of eribulin and lenvatinib as combination therapy for treatment of cancer
US9457019B2 (en) * 2013-11-07 2016-10-04 Deciphera Pharmaceuticals, Llc Methods for inhibiting tie-2 kinase useful in the treatment of cancer
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
US20170088626A1 (en) 2014-03-05 2017-03-30 Bristol-Myers Squibb Company Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
AU2015267099B2 (en) 2014-05-28 2020-08-27 Eisai R&D Management Co., Ltd Use of eribulin in the treatment of cancer
BR112017018872A2 (pt) 2015-03-04 2018-05-29 Eisai R&D Man Co Ltd combinação de um antagonista pd-1 e eribulina para tratamento de câncer

Also Published As

Publication number Publication date
MX386547B (es) 2025-03-19
SG11201706872SA (en) 2017-09-28
EP3265122B1 (en) 2022-05-04
BR112017018872A2 (pt) 2018-05-29
RU2017132877A (ru) 2019-04-05
MX2017011206A (es) 2018-05-17
KR20170122810A (ko) 2017-11-06
IL254133A0 (en) 2017-10-31
RU2737216C2 (ru) 2020-11-26
US20180071247A1 (en) 2018-03-15
AU2016226157A1 (en) 2017-09-14
JP6951248B2 (ja) 2021-10-20
EP3265122A1 (en) 2018-01-10
WO2016141209A1 (en) 2016-09-09
IL254133B (en) 2021-09-30
AU2016226157B2 (en) 2022-01-27
JP2018508516A (ja) 2018-03-29
US10945990B2 (en) 2021-03-16
RU2017132877A3 (cg-RX-API-DMAC7.html) 2019-08-29
CN107810013B (zh) 2021-04-02
CN107810013A (zh) 2018-03-16

Similar Documents

Publication Publication Date Title
US20220324979A1 (en) Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
US10945990B2 (en) Combination of a PD-1 antagonist and eribulin for treating cancer
US10695426B2 (en) Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
US9827309B2 (en) Treating cancer with a combination of a PD-1 antagonist and dinaciclib
US20200115451A1 (en) Compositions and methods for treating cancer with a combination of an antagonist of pd-1 and an anti-ctla4 antibody
US20190263927A1 (en) Combination of a pd-1 antagonist and eribulin for treating urothelial cancer
WO2020055702A1 (en) Combination of pd-1 antagonist and lag3 antagonist for treating non-microsatellite instablity-high/proficient mismatch repair colorectal cancer
HK40010365A (en) Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
HK40010365B (en) Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210302

EEER Examination request

Effective date: 20210302

EEER Examination request

Effective date: 20210302

FZDE Discontinued

Effective date: 20231003